Condition

Stage IV Ovarian Cancer AJCC v8

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 18 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials18

Recruiting2

Common interventions25

Lead sponsors shown10

Clinical trials

18 shown

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid TumorsNCT05733000 · 2023-03-08

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxNCT05092373 · 2022-04-29

Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast CancerNCT07226102 · 2026-07-16

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic CancerNCT06630325 · 2025-06-24

ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian CancerNCT05368506 · 2023-07-30

SMMART Adaptive Clinical Treatment (ACT) TrialNCT05238831 · 2023-01-30

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVNCT04514484 · 2021-11-22

ACTIVE_NOT_RECRUITING

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal CancerNCT04673448 · 2021-10-18

ACTIVE_NOT_RECRUITING

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial CancerNCT04491942 · 2021-08-25

ACTIVE_NOT_RECRUITING

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair VariationsNCT04550494 · 2021-04-26

ACTIVE_NOT_RECRUITING

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic CancerNCT04498520 · 2021-03-31

National Cancer Institute "Cancer Moonshot Biobank"NCT04314401 · 2020-11-11

ACTIVE_NOT_RECRUITING

Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported OutcomesNCT04501913 · 2019-12-24

Paclitaxel Therapeutic Drug Monitoring in Cancer PatientsNCT03987555 · 2019-11-11

A Phase I Study of SOR-C13 in Patients With Advanced Solid TumorsNCT03784677 · 2019-07-29

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot StudyNCT03707574 · 2019-07-16

Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV CancerNCT04067960 · 2019-06-06

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic InstabilityNCT03428802 · 2018-03-08

ACTIVE_NOT_RECRUITING

Common interventions

Leading sponsors

National Cancer Institute (NCI) 5 OHSU Knight Cancer Institute 3 City of Hope Medical Center 2 M.D. Anderson Cancer Center 2 Mayo Clinic 1 Northwestern University 1 Pamela Munster 1 Rutgers, The State University of New Jersey 1 University of Washington 1 Wake Forest University Health Sciences 1

Trial status mix

ACTIVE_NOT_RECRUITING6

COMPLETED4

WITHDRAWN4

RECRUITING2

SUSPENDED1

TERMINATED1

Phase mix

PHASE16

PHASE24

EARLY_PHASE13

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.